The Impact of Mutational Hotspots on Cancer Survival

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Mar 13

PMID 38473427

Authors

Melissa Gonzalez-Cardenas

Victor Trevino

Affiliations

Soon will be listed here.

Abstract

Background: Cofactors, biomarkers, and the mutational status of genes such as TP53, EGFR, IDH1/2, or PIK3CA have been used for patient stratification. However, many genes exhibit recurrent mutational positions known as hotspots, specifically linked to varying degrees of survival outcomes. Nevertheless, few hotspots have been analyzed (e.g., TP53 and EGFR). Thus, many other genes and hotspots remain unexplored.

Methods: We systematically screened over 1400 hotspots across 33 TCGA cancer types. We compared the patients carrying a hotspot against (i) all cases, (ii) gene-mutated cases, (iii) other mutated hotspots, or (iv) specific hotspots. Due to the limited number of samples in hotspots and the inherent group imbalance, besides Cox models and the log-rank test, we employed VALORATE to estimate their association with survival precisely.

Results: We screened 1469 hotspots in 6451 comparisons, where 314 were associated with survival. Many are discussed and linked to the current literature. Our findings demonstrate associations between known hotspots and survival while also revealing more potential hotspots. To enhance accessibility and promote further investigation, all the Kaplan-Meier curves, the log-rank tests, Cox statistics, and VALORATE-estimated null distributions are accessible on our website.

Conclusions: Our analysis revealed both known and putatively novel hotspots associated with survival, which can be used as biomarkers. Our web resource is a valuable tool for cancer research.

Citing Articles

Validation of a Compact and Self-Contained Pyrosequencing Platform for Clinical Screening of Mutations in Thyroid Cancers.

Burkhardt A, Smith C, Singh R Diagnostics (Basel). 2025; 15(3).

PMID: 39941320 PMC: 11817209. DOI: 10.3390/diagnostics15030390.

Key wound healing genes as diagnostic biomarkers and therapeutic targets in uterine corpus endometrial carcinoma: an integrated in silico and in vitro study.

Jiang F, Ahmad S, Kanwal S, Hameed Y, Tang Q Hereditas. 2025; 162(1):5.

PMID: 39833941 PMC: 11748876. DOI: 10.1186/s41065-025-00369-9.

References

Sullivan R, LoRusso P, Boerner S, Dummer R . Achievements and challenges of molecular targeted therapy in melanoma. Am Soc Clin Oncol Educ Book. 2015; :177-86. DOI: 10.14694/EdBook_AM.2015.35.177. View

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

Ignatiadis N, Klaus B, Zaugg J, Huber W . Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat Methods. 2016; 13(7):577-80. PMC: 4930141. DOI: 10.1038/nmeth.3885. View

Trevino V, Tamez-Pena J . VALORATE: fast and accurate log-rank test in balanced and unbalanced comparisons of survival curves and cancer genomics. Bioinformatics. 2017; 33(12):1900-1901. DOI: 10.1093/bioinformatics/btx080. View

Trevino V . HotSpotAnnotations-a database for hotspot mutations and annotations in cancer. Database (Oxford). 2020; 2020. PMC: 7211031. DOI: 10.1093/database/baaa025. View

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W . Exon 3 mutations of drive tumorigenesis: a review. Oncotarget. 2018; 9(4):5492-5508. PMC: 5797067. DOI: 10.18632/oncotarget.23695. View

Liu Y, Duan X, Zhang C, Yuan J, Wen J, Zheng C . KAT6B May Be Applied as a Potential Therapeutic Target for Glioma. J Oncol. 2022; 2022:2500092. PMC: 9007634. DOI: 10.1155/2022/2500092. View

Soares D, Barlow P, Newbery H, Porteous D, Abbott C . Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS One. 2009; 4(7):e6315. PMC: 2712093. DOI: 10.1371/journal.pone.0006315. View

10.

Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E . Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016; 7:10615. PMC: 4743009. DOI: 10.1038/ncomms10615. View

11.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

12.

Trevino V . Modeling and analysis of site-specific mutations in cancer identifies known plus putative novel hotspots and bias due to contextual sequences. Comput Struct Biotechnol J. 2020; 18:1664-1675. PMC: 7339035. DOI: 10.1016/j.csbj.2020.06.022. View

13.

Gutiontov S, Turchan W, Spurr L, Rouhani S, Chervin C, Steinhardt G . CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021; 11(1):20059. PMC: 8501138. DOI: 10.1038/s41598-021-99524-1. View

14.

Munch-Petersen H, Asmar F, Dimopoulos K, Areskeviciute A, Brown P, Girkov M . TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. Acta Neuropathol Commun. 2016; 4:40. PMC: 4840983. DOI: 10.1186/s40478-016-0307-6. View

15.

Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View

16.

Vandin F, Papoutsaki A, Raphael B, Upfal E . Accurate computation of survival statistics in genome-wide studies. PLoS Comput Biol. 2015; 11(5):e1004071. PMC: 4423942. DOI: 10.1371/journal.pcbi.1004071. View

17.

Huang C, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu V, Kinzler K . The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007; 318(5857):1744-8. DOI: 10.1126/science.1150799. View

18.

Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R . K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000; 60(23):6750-6. View

19.

Du X, Shao Y, Qin H, Tai Y, Gao H . ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018; 9(4):423-430. PMC: 5879058. DOI: 10.1111/1759-7714.12613. View

20.

Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D . T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. Clin Cancer Res. 2021; 28(2):378-389. PMC: 9401455. DOI: 10.1158/1078-0432.CCR-21-1881. View